Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
Background. Non-alcoholic fatty liver disease (NAFLD) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited.Summary. L-ornithine L-aspartate (LOLA) has hepatoprotective properties in patients with fatty liver of diverse etiology and results of...
Saved in:
Main Authors: | Roger F. Butterworth, Ali Canbay |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Gastro LLC
2019-03-01
|
Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
Subjects: | |
Online Access: | https://www.gastro-j.ru/jour/article/view/322 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Application of ursodeoxycholic acid at non-alcoholic and alcohol-induced steatohepatitis
by: Ye. A. Fedos’ina, et al.
Published: (2010-06-01) -
Epidemiologic features of non-alcoholic fatty liver disease in Russia
by: O. M. Drapkina, et al.
Published: (2014-10-01) -
Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01) -
Combination of autoimmune hepatitis to non-alcoholic steatohepatitis (Clinical case)
by: A. A. Driga, et al.
Published: (2010-11-01) -
Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)